|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-24
|
|
pubmed:abstractText |
Platelet inhibition as measured by vasodilator-stimulated phosphoprotein (VASP) and light transmission aggregometry (LTA) have shown concordance following dosing of clopidogrel. No reports have directly compared the VASP assay and LTA at the levels of P2Y(12) blockade after loading doses (LDs) of prasugrel or high dose clopidogrel (600 and 900 mg). The aim was to compare the VASP assay and LTA during the loading dose phase of a comparative study of prasugrel and clopidogrel. Prasugrel 60 mg LD/10 mg maintenance dose (MD) and clopidogrel 300 mg/75 mg and 600 mg/75 mg LD/MD regimens were compared in a 3-way crossover study in 41 healthy, aspirin-free subjects. Each LD was followed by seven daily MDs and a 14-day washout period. P2Y(12) receptor blockade was estimated using the VASP assay, expressed as platelet reactivity index (VASP-PRI). Platelet aggregation was assessed by light transmission aggregometry (20 and 5 microM ADP). Twenty-four hours after prasgurel 60 mg or clopidogrel 300 mg and 600 mg, respectively, VASP-PRI decreased from approximately 80% to 8.9%, 54.7%, and 39.0%, and maximal platelet aggregation (MPA) decreased from approximately 79% to 10.8%, 42.7%, and 31.2%, with an overall VASP:MPA correlation of 0.88 (p < 0.01). VASP assay responses after the clopidogrel LDs showed a wider range of values (300 mg: 0-93%; 600 mg: 0-80%) than prasugrel (0-13%); MPA responses followed a similar trend. Pearson's correlation suggested a strong agreement between VASP and LTA (20 microM ADP) for MPA (r = 0.86, p < 0.0001). VASP and LTA demonstrated concordance across the response range of P2Y(12) receptor blockade following thienopyridine LDs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Diphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules,
http://linkedlifedata.com/resource/pubmed/chemical/Microfilament Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/P2RY12 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Purinergic P2 Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Purinergic P2Y12,
http://linkedlifedata.com/resource/pubmed/chemical/Thiophenes,
http://linkedlifedata.com/resource/pubmed/chemical/Ticlopidine,
http://linkedlifedata.com/resource/pubmed/chemical/clopidogrel,
http://linkedlifedata.com/resource/pubmed/chemical/prasugrel,
http://linkedlifedata.com/resource/pubmed/chemical/vasodilator-stimulated...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0340-6245
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
215-22
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18217157-Adenosine Diphosphate,
pubmed-meshheading:18217157-Adult,
pubmed-meshheading:18217157-Blood Platelets,
pubmed-meshheading:18217157-Cell Adhesion Molecules,
pubmed-meshheading:18217157-Cross-Over Studies,
pubmed-meshheading:18217157-Dose-Response Relationship, Drug,
pubmed-meshheading:18217157-Drug Administration Schedule,
pubmed-meshheading:18217157-Female,
pubmed-meshheading:18217157-Flow Cytometry,
pubmed-meshheading:18217157-Humans,
pubmed-meshheading:18217157-Light,
pubmed-meshheading:18217157-Male,
pubmed-meshheading:18217157-Microfilament Proteins,
pubmed-meshheading:18217157-Middle Aged,
pubmed-meshheading:18217157-Phosphoproteins,
pubmed-meshheading:18217157-Phosphorylation,
pubmed-meshheading:18217157-Piperazines,
pubmed-meshheading:18217157-Platelet Aggregation,
pubmed-meshheading:18217157-Platelet Aggregation Inhibitors,
pubmed-meshheading:18217157-Platelet Function Tests,
pubmed-meshheading:18217157-Purinergic P2 Receptor Antagonists,
pubmed-meshheading:18217157-Receptors, Purinergic P2,
pubmed-meshheading:18217157-Receptors, Purinergic P2Y12,
pubmed-meshheading:18217157-Reproducibility of Results,
pubmed-meshheading:18217157-Thiophenes,
pubmed-meshheading:18217157-Ticlopidine,
pubmed-meshheading:18217157-Time Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
|
|
pubmed:affiliation |
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. joseph@lilly.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
